CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT
NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF SEMAGLUTIDE INJECTION

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the application for marketing approval of Semaglutide Injection (the "**Product**") developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., a subsidiary of the Company, has been accepted by the National Medical Products Administration (NMPA) of the People's Republic of China. The indication for this application is glycemic control in adult patients with type 2 diabetes.

The Product, a glucagon-like peptide-1 ("**GLP-1**") receptor agonist based on the structure of natural human GLP-1, is a semaglutide preparation produced through chemical synthesis and has been applied for as a Class 2.2 new drug under the registration classification of chemical drugs, which contains known active ingredients with new formulation process and has significant clinical advantages. GLP-1, a gut-derived hormone secreted by intestinal L cells, exerts its effects by binding to GLP-1 receptors widely distributed in various organs and tissues throughout the body, and achieves comprehensive benefits, such as glycemic control, weight reduction, and cardiovascular and renal protection, through multiple mechanisms.

This application is based on a pivotal Phase III clinical trial. The results of this clinical trial showed that in patients with type 2 diabetes who had inadequate glycemic control despite treatment with metformin, the Product demonstrated highly consistent efficacy and a slightly lower incidence of gastrointestinal reactions compared to semaglutide developed by Novo Nordisk. Through a series of studies in pharmaceutical, non-clinical, clinical pharmacokinetics, clinical efficacy and safety according to the relevant guidance, the Product has been scientifically, rigorously and completely proven to be highly consistent with semaglutide developed by Novo Nordisk.

Based on its advantages in efficacy, safety, formulation, the Product has significant clinical application value. The Group is also actively promoting the Phase III clinical trial of the Product for obesity/overweight indication, with the aim of benefiting more patients.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 5 August 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.